title: Adjuvant effect of antibodies against von Willebrand Factor, fibrinogen, and fibronectin on staphylokinase-induced thrombolysis as measured using mural thrombi formed in rat mesenteric venules.
abstract: The change in thrombus mass during thrombolytic therapy is thought to be the difference between its growth and its degradation induced by thrombolytic agents. Platelets play a pivotal role in arterial thrombosis and bind to each other and to exposed subendothelial matrices via adhesive proteins such as von Willebrand Factor, fibrinogen, and fibronectin. The aim of the present study was to assess whether administration of antibodies against these adhesive proteins, in conjunction with plasminogen activator, could enhance the degradation of platelet-rich thrombus. Mural platelet-rich thrombi were formed in rat mesenteric venules using He-Ne laser irradiation. Recombinant staphylokinase was infused continuously and polyclonal antibodies against adhesive proteins were given by bolus injection. The thrombolytic process was analysed using computer-enhanced image analysis software. Administration of each of the antibodies enhanced staphylokinase-induced thrombolysis.
authors.affiliation: Laboratory of Physiology, Faculty of Nutrition, Kobe Gakuin University, Japan. yamamoto@nutr.kobegakuin.ac.jp
authors.forename: J
authors.initials: J
authors.lastname: Yamamoto
authors.forename: M
authors.initials: M
authors.lastname: Kawano
authors.forename: M
authors.initials: M
authors.lastname: Hashimoto
authors.forename: Y
authors.initials: Y
authors.lastname: Sasaki
authors.forename: T
authors.initials: T
authors.lastname: Yamashita
authors.forename: T
authors.initials: T
authors.lastname: Taka
authors.forename: S
authors.initials: S
authors.lastname: Watanabe
authors.forename: J C
authors.initials: JC
authors.lastname: Giddings
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D005340:Fibrinogen / Q000187:drug effects* / Q000276:immunology; D005343:Fibrinolytic Agents / Q000494:pharmacology; D005353:Fibronectins / Q000187:drug effects* / Q000276:immunology; D006331:Heart Diseases / Q000188:drug therapy; D007106:Immune Sera / Q000494:pharmacology; D007074:Immunoglobulin G / Q000494:pharmacology*; D008297:Male; D008642:Mesenteric Veins; D008666:Metalloendopeptidases / Q000494:pharmacology*; D010960:Plasminogen Activators / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D015912:Thrombolytic Therapy; D013927:Thrombosis / Q000188:drug therapy*; D014841:von Willebrand Factor / Q000187:drug effects* / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D005343:Fibrinolytic Agents; D005353:Fibronectins; D007106:Immune Sera; D007074:Immunoglobulin G; D014841:von Willebrand Factor; D005340:Fibrinogen; D010960:Plasminogen Activators; D008666:Metalloendopeptidases; C022653:auR protein, Staphylococcus aureus